Search Within

Michael Morris

Formats
  1. Meeting Abstract (275)
  2. Journal Article (268)
  3. Review (20)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (586)
  2. Genitourinary Oncology Service (586)
  3. Solid Tumor Oncology Division (586)
  4. Radiology, Department of (164)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (141)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (27)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (240)
  2. Journal of Nuclear Medicine (44)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (250)
  2. Society of Nuclear Medicine (44)
  3. American Association for Cancer Research (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (40)
  6. Elsevier Inc. (27)

More Publishers

Results (586)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Automated bone scan index to optimize prostate cancer working group radiographic progression criteria for men with metastatic castration-resistant prostate cancer
    Journal Article

    Anand, A.; Heller, G.; Fox, J.; Danila, D. C.; Bjartell, A.; Edenbrandt, L.; Larson, S. M.; Scher, H. I.; Morris, M. J.
    Clinical Genitourinary Cancer (2022)

    Fulltext@MSK | Save
  • Evolving role of prostate-specific membrane antigen-positron emission tomography in metastatic hormone-sensitive prostate cancer: More questions than answers?
    Editorial

    Hussain, M.; Carducci, M. A.; Clarke, N.; Fenton, S. E.; Fizazi, K.; Gillessen, S.; Jacene, H.; Morris, M. J.; Saad, F.; Sartor, O.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PSMAfore: A phase 3 study to compare (177)Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Sartor, A. O.; Morris, M. J.; Chi, K. N.; De Bono, J. S.; Shore, N. D.; Crosby, M.; Kreisl, T. N.; Fizazi, K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Sartor, A. O.; Tagawa, S. T.; Saad, F.; De Bono, J. S.; Feng, F. Y.; Fizazi, K.; Sakharova, O. V.; Morris, M. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Use of bone modifying agents for metastatic castrate-resistant prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Mishra Meza, A.; Farooki, A.; Panageas, K.; Bach, P. B.; Lipitz-Snyderman, A.; Morris, M. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer
    Meeting Abstract

    Morris, M. J.; Sartor, A. O.; Wong, J. Y. C.; Max, S. I.; Xie, H.; Russell, M.; Divgi, C. R.; Patricia, D.; Avadhani, A. N.; Nordquist, L. T.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score
    Meeting Abstract

    Gorin, M. A.; Rowe, S. P.; Pienta, K. J.; Carroll, P. R.; Pouliot, F.; Probst, S.; Saperstein, L.; Preston, M.; Alva, A. S.; Patnaik, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Prostate-specific membrane antigen-targeted theranostics: Past, present, and future approaches
    Review

    Hawkey, N. M.; Sartor, A. O.; Morris, M. J.; Armstrong, A. J.
    Clinical Advances in Hematology & Oncology (2022)

    Fulltext@MSK | Save